Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2024-514216-27-00 | EU Trial (CTIS) Number | ||
| CTR20244018 | Registry Identifier | ChinaDrugTrials |
Not provided
Not provided
Not provided
Sponsor Decision
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of BGB-B3227, a humanized immunoglobulin G1 (IgG1) antibody. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-B3227 as a monotherapy or in combination with tislelizumab with or without chemotherapy in participants with selected advanced or metastatic solid tumors. The study will also identify recommended dose(s) for expansion (RDFE[s]) of BGB-B3227 administered alone and in combination with tislelizumab.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Phase 1a Part A: Dose Escalation (BGB-B3227 Monotherapy) | Experimental | Sequential cohorts of increasing dose levels of BGB-B3227 will be evaluated as monotherapy. |
|
| Phase 1a Part B: Dose Escalation (BGB-B3227 + tislelizumab) | Experimental | Sequential cohorts of increasing dose levels of BGB-B3227 will be evaluated in combination with tislelizumab. |
|
| Phase 1b: Dose Expansion | Experimental | Sequential cohorts of increasing dose levels of BGB-B3227 will be evaluated in combination with tislelizumab and chemotherapy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BGB-B3227 | Drug | Administered intravenously. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Number of participants with AEs and SAEs, including findings from physical examinations, laboratory assessments, and that meet protocol-defined dose-limiting toxicity (DLT) criteria or protocol-defined Adverse Event of Special Interest (AESI) criteria. | From first dose of the study drug(s) to 30 days after the last dose or 90 days after last dose of tislelizumab, approximately 9 months |
| Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) | MTD is defined as the highest dose evaluated for which estimated toxicity rate is the closest to the target toxicity rate. MAD is defined as the highest dose administered if MTD is not reached. | Approximately 9 months |
| Phase 1a: Recommended Dose(s) for Expansion (RDFE[s]) of BGB-B3227 | RDFE of BGB-B3227 alone or in combination with tislelizumab will be determined based upon the MTD or MAD. | Approximately 9 months |
| Phase 1b: Objective Response Rate (ORR) | ORR is defined as the percentage of participants with confirmed best overall response of complete response (CR) or partial response (PR), as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. | From first dose of study drug(s) until progressive disease or new anticancer treatment; approximately 12 months |
| Phase 1b: Recommended Phase 2 Dose (RP2D) of BGB-B3227 | RP2D established from Phase 1a for BGB-B3227 for administration in combination with tislelizumab and chemotherapy in selected tumor types. | Approximately 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Phase 1a: ORR | ORR is defined as the percentage of participants with confirmed best overall response of CR or PR, as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. | From first dose of study drug(s) until progressive disease or new anticancer treatment; approximately 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Study Director | BeiGene | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Usc Norris Comprehensive Cancer Center (Nccc) | Los Angeles | California | 90089-1019 | United States | ||
| Washington University in St Louis |
BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
See plan description
See plan description
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Tislelizumab | Drug | Administered intravenously. |
|
|
| Chemotherapy | Drug | Administered in accordance with relevant local guidelines and/or prescribing information. |
|
| Phase 1b: Progression-Free Survival (PFS) |
PFS is defined as the time from the first dose of study treatment to the date of first documentation of disease progression or death, whichever occurs first, as assessed by the investigator per RECIST Version 1.1. |
| From first dose of study drug(s) until progressive disease or new anticancer treatment; approximately 12 months |
| Phase 1b: Number of Participants with AEs and SAEs | Number of participants with AEs and SAEs, including findings from physical examinations, laboratory assessments, and that meet protocol-defined dose-limiting toxicity (DLT) criteria or protocol-defined Adverse Event of Special Interest (AESI) criteria. | From first dose of the study drug(s) to 30 days after the last dose, or 90 days after last dose of tislelizumab; approximately 12 months |
| Phase 1a and 1b: Disease Control Rate (DCR) | DCR is defined as the percentage of participants who achieve confirmed CR, PR, or stable disease, as assessed by the investigator per RECIST Version 1.1. | From first dose of study treatment drug(s) until confirmed response or stable disease; approximately 6 months for Phase 1a and 12 months for Phase 1b |
| Phase 1a and 1b: Duration of Response (DoR) | DoR is defined as the time from the first confirmed objective response to disease progression documented after treatment initiation or death, whichever occurs first, as assessed by the investigator per RECIST Version 1.1. | From confirmed response to disease progression or death; approximately 6 months for Phase 1a and 12 months for Phase 1b |
| Phase 1a and 1b: Serum Concentrations of BGB-B3227 | From first dose of BGB-B3227 up to 30 days after last dose of BGB-B3227; approximately 6 months for Ph1a and 12 months for Ph1b |
| Phase 1a and 1b: Number of Participants with Antidrug Antibodies (ADAs) against BGB-B3227 | From first dose of BGB-B3227 up to 30 days after last dose of BGB-B3227; approximately 6 months for Phase 1a and 12 months for Phase 1b |
| Phase 1a: Area under the Curve (AUC) of BGB-B3227 | Approximately 4 months |
| Phase 1a: Maximum observed plasma concentration (Cmax) of BGB-B3227 | Approximately 4 months |
| Phase 1a: Time to reach maximum observed plasma concentration (Tmax) of BGB-B3227 | Approximately 4 months |
| Phase 1a: Trough concentration (Ctrough) of BGB-B3227 | Approximately 4 months |
| Phase 1a: Accumulation ratio of BGB-B3227 | Approximately 4 months |
| Phase 1a: Terminal half-life (t1/2) of BGB-B3227 | Approximately 4 months |
| St Louis |
| Missouri |
| 63110-1010 |
| United States |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601-1915 | United States |
| Next Oncology | Austin | Texas | 78758 | United States |
| Md Anderson Cancer Center | Houston | Texas | 77030-3907 | United States |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing | Beijing Municipality | 100021 | China |
| Beijing Cancer Hospital | Beijing | Beijing Municipality | 100142 | China |
| Affiliated Zhongshan Hospital of Fudan University | Shanghai | Shanghai Municipality | 200032 | China |
| Fondazione Irccs Istituto Nazionale Dei Tumori | Milan | 20133 | Italy |
| Istituto Europeo Di Oncologia | Milan | 20141 | Italy |
| Fondazione Policlinico Universitario Agostino Gemelli | Roma | 00168 | Italy |
| Istituto Clinico Humanitas | Rozzano | 20089 | Italy |
| ID | Term |
|---|---|
| D009362 | Neoplasm Metastasis |
| ID | Term |
|---|---|
| D009385 | Neoplastic Processes |
| D009369 | Neoplasms |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C000707970 | tislelizumab |
| D004358 | Drug Therapy |
| ID | Term |
|---|---|
| D013812 | Therapeutics |
Not provided
Not provided